证券代码：600998 证券简称：九州通 公告编号：临 2026-001 九州通医药集团股份有限公司 关于召开2026年第一次临时股东会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 九州通医药集团股份有限公司（以下简称"公司"）已于2025年12月20日 在《中国证券报》《上海证券报》《证券时报》《证券日报》及上海证券交易 所网站（www.sse.com.cn）上披露了《关于召开2026年第一次临时股东会的通 知》（公告编号：临2025-094），公司将于2026年1月7日召开2026年第一次临 时股东会，根据相关规定，现发布本次股东会的提示性公告，具体内容如下： 一、 召开会议的基本情况 （一）股东会类型和届次 （二）股东会召集人：董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的 方式 （四）现场会议召开的日期、时间和地点 股东会召开日期：2026年1月7日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 召开的日期时间：2026 年 1 月 7 ...

Core Viewpoint - 九州通 has successfully completed the restructuring investment plan for Aoyuan Meigu, acquiring its core assets for 706 million yuan, marking a strategic entry into the medical beauty sector [1][2][4] Group 1: Company Overview - Aoyuan Meigu, established in 1993 and formerly known as Hubei Jinhui, transitioned into the medical beauty industry after being acquired by Aoyuan Group in 2020 [2] - The company primarily focuses on bio-based fibers and medical beauty services, operating two high-end medical beauty hospitals with over 330,000 members and 80,000 active members annually [2] - In 2024, Aoyuan Meigu's medical beauty business is projected to generate 624 million yuan in revenue, accounting for 57% of total revenue [2] Group 2: Financial and Operational Challenges - Aoyuan Meigu has faced continuous operating losses and a debt crisis, leading to its stock being marked with "delisting risk warning" in 2023 [2] - The company was unable to repay due debts, prompting creditors to apply for restructuring in November 2024, which was approved by the court in December [3][4] Group 3: Strategic Implications for 九州通 - 九州通, as a leading private pharmaceutical distribution company, has built a comprehensive supply chain service platform and has been involved in the medical beauty sector for over 10 years [5][6] - The acquisition of Aoyuan Meigu allows 九州通 to establish a full-chain layout from upstream procurement to downstream service terminals, enhancing its competitive edge [6][7] - The domestic medical beauty market has surpassed 300 billion yuan, with an annual growth rate exceeding 18%, presenting significant opportunities for 九州通 to leverage its supply chain and improve profitability [6][7]

证券代码：600998 证券简称：九州通 公告编号：临 2025-099 九州通医药集团股份有限公司 关于股东提前解除股份质押及质押的公告 2025年12月29日，九州通医药集团股份有限公司（以下简称"公司"）收到股东上 海弘康实业投资有限公司（以下简称"上海弘康"）的通知，获悉上海弘康持有本公司 的部分股份已办理完成提前解除质押及质押手续。具体情况如下： 一、本次股份提前解除质押的相关情况 上海弘康办理完成125,600,000股（占公司总股本的2.49%）股份的提前解除质押手 续，具体情况如下： | 股东名称 | 上海弘康 | | --- | --- | | 本次解除质押股份（股） | 125,600,000 | | 占其所持股份比例 | 11.54% | | 占公司总股本比例 | 2.49% | | 解除质押时间 | 2025/12/29 | | 持股数量（股） | 1,088,326,782 | | 持股比例 | 21.58% | | 剩余被质押股份数量（股） | 528,724,549 | | 剩余被质押股份数量占其所持股份比例 | 48.58% | | 剩余被质押股份数量占公司总股本比例 | 10 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.0% on December 30, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3965.12, also down by 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Yingte Group (000411) with a closing price of 13.23, up by 9.98% and a trading volume of 419,800 shares [1] - Yao Yigou (300937) at 35.65, up by 7.64% with 125,700 shares traded [1] - HeFu China (603122) at 26.00, up by 6.17% with a trading volume of 985,200 shares [1] - Conversely, Saily Medical (603716) saw a decline of 3.19% to a closing price of 20.95, with a trading volume of 123,200 shares [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 258 million yuan from institutional investors, while retail investors contributed a net inflow of 54.61 million yuan [2] - Notable capital flows included: - HeFu China (603122) with a net inflow of 286 million yuan from institutional investors [3] - Yingte Group (000411) with a net inflow of 134 million yuan from institutional investors [3] - Yao Yigou (300937) with a net inflow of 16.36 million yuan from institutional investors [3]

Core Insights - The article highlights the significant achievements and strategic direction of Jiuzhoutong Group, emphasizing its dual listing and extensive logistics network coverage across China [3][4]. Group 1: Company Achievements - Jiuzhoutong Group participated in a meeting for private enterprises, reflecting the support from the government for business development [3]. - The company has launched a dual listing, becoming the only dual-listed company in the Chinese pharmaceutical industry, with its public REITs debut on February 27 [3]. - Jiuzhoutong celebrated its 40th anniversary with impressive financial results, reporting over 150 billion yuan in revenue for two consecutive years, and operates 687 subsidiaries with a logistics network covering over 96% of administrative regions in China [3]. Group 2: Strategic Initiatives - The company is advancing its "Three New and Two Transformations" strategy, focusing on new products, new retail, new healthcare, digitalization, and real estate securitization [3]. - Jiuzhoutong has been recognized as the 55th in the latest list of China's top 500 private enterprises and ranks 4th in the pharmaceutical commercial industry, leading as the top private pharmaceutical distributor [4].

Core Viewpoint - 九州通医药集团股份有限公司's wholly-owned subsidiary, Hubei Jiuzhou Industrial Park Operation Management Co., Ltd., has successfully completed the restructuring investment in Aoyuan Meigu Technology Co., Ltd., with the restructuring plan approved and executed as of December 29, 2025 [4][10]. Group 1: Restructuring Investment Overview - On April 23, 2025, 九州通's subsidiary signed a restructuring investment agreement with Aoyuan Meigu and its temporary administrator, committing to invest CNY 673.2 million for 360 million shares post-restructuring [2][5]. - A supplementary agreement was signed on September 24, 2025, adjusting the investment plan, with the number of shares to be acquired increased to 435,930,312 shares for a total investment of CNY 706.207 million [6]. Group 2: Court Proceedings and Restructuring Plan - On November 14, 2025, the Xiangyang Intermediate People's Court accepted Aoyuan Meigu's restructuring application and appointed a management team [3][7]. - The court approved the restructuring plan on December 16, 2025, leading to the termination of the restructuring process [4][11]. - The restructuring process was officially concluded on December 29, 2025, with all obligations under the restructuring plan fulfilled [8][9]. Group 3: Impact on Company Operations and Financials - The restructuring investment aligns with the company's long-term strategic development, enhancing its core competitiveness and enabling collaboration in the beauty and health sector [10]. - The completion of the restructuring is not expected to have a significant short-term impact on the company's financial performance, and there are no adverse effects on the interests of the company and its shareholders [11].

2025 年 11 月 14 日，奥园美谷收到湖北省襄阳市中级人民法院（以下简 称"襄阳中院"）送达的《民事裁定书》及《决定书》，襄阳中院裁定受理奥园美 谷重整申请，并指定奥园美谷清算组担任奥园美谷管理人。具体详见公司于 2025 年 11 月 17 日在上海证券交易所网站（www.sse.com.cn）披露的《九州通关于全 资子公司参与重整投资的奥园美谷科技股份有限公司获法院裁定受理重整并指 定管理人的进展公告》（公告编号：临 2025-082）。 2025 年 12 月 16 日，奥园美谷收到襄阳中院送达的《民事裁定书》（（2025） 鄂 06 破 17 号），襄阳中院裁定批准《奥园美谷科技股份有限公司重整计划》（以 下简称"《重整计划》"），并终止奥园美谷重整程序。具体详见公司于 2025 年 12 证券代码：600998 证券简称：九州通 公告编号：临 2025-098 九州通医药集团股份有限公司 关于全资子公司参与重整投资的奥园美谷科技股份有限公司 重整计划执行完毕的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 ...

Core Viewpoint - The announcement indicates that a subsidiary of the company has received regulatory approval for a new drug, which may enhance its product portfolio and market position in the pharmaceutical industry [2] Group 1 - On December 26, the company announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received a drug registration certificate for Isopropamide Iodide Injection from the National Medical Products Administration [2] - The approval is significant as it allows the company to market and distribute this medication, potentially increasing its revenue streams [2] - The drug registration certificate was issued on December 25, 2025, marking a key milestone in the company's product development timeline [2]

Group 1 - Zhuolang Intelligent's subsidiary plans to increase capital by 900 million yuan to its wholly-owned subsidiary in Xinjiang [1] - Zhenhua Heavy Industry signed a contract worth 1.149 billion yuan with Guangzhou Salvage Bureau for a deep-water crane ship construction project [2] - Ugreen Technology intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy [3] Group 2 - Guangsheng Nonferrous Metals will change its stock name to Zhongxi Rare Metals starting December 31, 2025 [4] - China Electric Research proposed a cash dividend of 2.5 yuan per 10 shares for the first three quarters of 2025 [5] - Chaoyan Co. is establishing a fund with professional investment institutions, aiming to raise 1 billion yuan [6] Group 3 - Silk Road Vision's subsidiary plans to sell 8.5% of Ruijun Technology for 52.7 million yuan [7] - Longgao Co.'s actual controller is transferring 4.37% of the investment development group's equity for 398 million yuan [8] - Weiteou signed a strategic cooperation agreement with Huaruixin Energy to develop new materials and applications [9][10] Group 4 - Annuoqi decided to terminate the investment in a 50,000-ton dye intermediate project due to market changes, with a total investment of 421 million yuan [12] - Akoli's subsidiary has entered trial production for a project with an annual capacity of 20,000 tons of polyether amine [13] - Ningbo Construction's subsidiary signed a construction contract worth 451 million yuan for a comprehensive utility tunnel project [14] Group 5 - Zhejiang Rongtai and Weichuang Electric plan to establish a joint venture in Thailand for R&D and production of mechatronic components [15] - Jiuzhoutong's subsidiary received a drug registration certificate for isopropazine injection [16] - Huaqin Technology's subsidiary signed a daily operation contract worth 392 million yuan [17] Group 6 - ST Meichen completed the sale of 100% equity in Hainan Meichen Ecological Development Co., Ltd. [18] - Pulite's LCP film products have begun mass production for a leading customer in the consumer electronics industry [19][20] - Nanjing Public Utility's major shareholder transferred 7.61% of the company's shares for 300 million yuan [21] Group 7 - Solar Energy terminated the investment in a 150 MW distributed photovoltaic project due to increased investment risks [22] - Yuntian Lifa won a 122 million yuan project for AI development in Longgang [23] - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci141 ointment [24] Group 8 - Changfei Optical Fiber's major shareholder completed a share reduction plan, selling 1.1 million shares for approximately 104.5 million yuan [25] - Sandam Membrane plans to apply for a comprehensive credit limit of up to 100 million yuan for 2026 [26] - Aisecurity received a government subsidy of 3.4611 million yuan [27] Group 9 - Stone Technology's H-share issuance has received approval from the China Securities Regulatory Commission [28] - Hongxing Development's subsidiary plans to suspend production to comply with national hazardous chemical relocation policies [29] - Guodian Nanzi's vice president and chief engineer resigned [30] Group 10 - Jianghe Group's subsidiary won a bid for a city renovation project in Haikou worth approximately 112 million yuan [31] - Gaotie Electric's subsidiary won a bid for a railway project worth 59.0317 million yuan [32] - Huicheng Co. plans to introduce a new partner to its major shareholder [33] Group 11 - Pumen Technology's folic acid testing kit received a medical device registration certificate [34] - Hai Xin Co.'s vitamin B6 injection passed the consistency evaluation for generic drugs [35] - Taiji Group's shareholder plans to merge with its subsidiary [36] Group 12 - Shengyi Electronics adjusted the maximum repurchase price to no more than 144.36 yuan per share [37]

证券代码：600998 证券简称：九州通 公告编号：临 2025-097 九州通医药集团股份有限公司 关于盐酸异丙嗪注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 12 月 25 日，九州通医药集团股份有限公司（以下简称"公司"或 "九州通"）子公司北京京丰制药集团有限公司（以下简称"京丰制药"）的下 属公司汇禹远和（海南）药业有限公司（以下简称"汇禹远和"）收到国家药品 监督管理局核准签发的盐酸异丙嗪注射液《药品注册证书》。现将相关情况公告 如下： 一、药品注册证书主要信息 药品名称：盐酸异丙嗪注射液 剂型：注射剂 申请事项：药品注册（境内生产） 规格：2ml：50mg；1ml：25mg 注册分类：化学药品 3 类 证书编号：2025S03881；2025S03882 药品批准文号：国药准字 H20256348；国药准字 H20256349 药品批准文号有效期：至 2030 年 12 月 21 日 上市许可持有人：汇禹远和（海南）药业有限公司 药品生产企业：浙江赛默制药有限公司 审 ...